| Symbol | ZLDAF |
|---|---|
| Name | ZELIRA THERAPEUTICS LTD. |
| Sector | UNDEFINED |
| Region | Oceania |
| Industry | - |
| Address | 6000 Australia WA Level 3, 101 St Georges Terrace |
| Telephone | +61 8 6558 0886 |
| Fax | — |
| — | |
| Website | https://www.zeliratx.com/ |
| Incorporation | AU |
| Incorporated On | 2003 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Hall Chadwick; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | Zelira Therapeutics Ltd is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain as well as offering over the counter (OTC) products Additional info from OTC: |
No news found.